10-K.Info (Beta Test)
Courtesy of Short Sands, LLC
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

GILEAD SCIENCES, INC.

Ticker: GILD   Fiscal Year: 2017

Consolidated Statements of Income

Period Ending Dec 31, 2017 10-K (Filed: Feb 27, 2018)

(In Millions)
 12 Months Ended12 Months Ended12 Months Ended
 Dec 31, 2017Dec 31, 2016Dec 31, 2015
Revenues
Product sales
$
25,662
29,95332,151
Royalty, contract and other revenues445437488
Total revenues26,10730,39032,639
 
Costs and Expenses
Cost of goods sold4,3714,2614,006
Research and development expenses3,7345,0983,014
Selling, general and administrative expenses3,8783,3983,426
Total costs and expenses11,98312,75710,446
 
Income from operations14,12417,63322,193
Interest expense(1,118)(964)(688)
Other income (expense), net523428154
Income before provision for income taxes13,52917,09721,659
 
Provision for income taxes8,8853,6093,553
Net income4,64413,48818,106
 
Net income (loss) attributable to noncontrolling interest16(13)(2)
Net income attributable to Gilead4,62813,50118,108
 
Net income per share attributable to Gilead common stockholders - basic3.5410.0812.37
Shares used in per share calculation - basic1,3071,3391,464
Net income per share attributable to Gilead common stockholders - diluted3.519.9411.91
Shares used in per share calculation - diluted1,3191,3581,521
Cash dividends declared per share2.081.841.29
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

GILEAD SCIENCES, INC.

Ticker: GILD   Fiscal Year: 2017

Consolidated Statements of Comprehensive Income

Period Ending Dec 31, 2017 10-K (Filed: Feb 27, 2018)

(In Millions, except shares in actual)
 12 Months Ended12 Months Ended12 Months Ended
 Dec 31, 2017Dec 31, 2016Dec 31, 2015
Net income
$
4,644
13,48818,106
Other Comprehensive Income (Loss)
Net foreign currency translation gain (loss), net of tax(47)1779
Available-for-sale Securities
Net unrealized gain (loss), net of tax impact of $6, $19 and $(17), respectively2187(29)
Reclassifications to net income, net of tax impact of $(9), $0 and $1, respectively(8)(7)1
Net change2100(28)
 
Cash Flow Hedges
Net unrealized gain (loss), net of tax impact of $(11), $0 and $21, respectively(304)5389
Reclassification to net income, net of tax impact of $0, $(8) and $(19), respectively288(583)
Net change(276)13(194)
 
Other comprehensive income (loss)(113)190(213)
 
Comprehensive income4,53113,67817,893
 
Comprehensive income (loss) attributable to noncontrolling interest16(13)(2)
Comprehensive income attributable to Gilead4,51513,69117,895
 
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

GILEAD SCIENCES, INC.

Ticker: GILD   Fiscal Year: 2017

Consolidated Statements of Cash Flows

Period Ending Dec 31, 2017 10-K (Filed: Feb 27, 2018)

(In Millions, except shares in actual)
 12 Months Ended12 Months Ended12 Months Ended
 Dec 31, 2017Dec 31, 2016Dec 31, 2015
Operating Activities:
Net income
$
4,644
13,48818,106
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation expense233177161
Amortization expense1,053981937
Stock-based compensation expense638380382
Deferred income taxes(82)(119)(393)
In-process research and development impairment04320
Other304162562
Changes in operating assets and liabilities:
Accounts receivable, net7541,192(1,397)
Inventories(253)(488)(855)
Prepaid expenses and other358(520)(90)
Accounts payable(430)47226
Income taxes payable5,4971,010269
Accrued liabilities(818)3053,342
Net cash provided by operating activities11,89817,04721,250
 
Investing Activities:
Purchases of marketable securities(23,314)(25,619)(17,239)
Proceeds from sales of marketable securities10,44013,0394,792
Proceeds from maturities of marketable securities7,8211,700719
Other investments0(357)0
Acquisitions, net of cash acquired(10,426)00
Capital expenditures(590)(748)(747)
Net cash used in investing activities(16,069)(11,985)(12,475)
 
Financing Activities:
Proceeds from debt financing, net of issuance costs8,9855,2939,902
Proceeds from convertible note hedges0956784
Proceeds from issuances of common stock234208319
Repurchases of common stock(954)(11,001)(10,002)
Repayments of debt and other obligations(1,811)(1,981)(997)
Payments to settle warrants0(469)(3,865)
Payment of dividends(2,731)(2,455)(1,874)
Other(330)(276)(151)
Net cash provided by (used in) financing activities3,393(9,725)(5,884)
 
Effect of exchange rate changes on cash and cash equivalents13741(67)
Net change in cash and cash equivalents(641)(4,622)2,824
 
Cash and cash equivalents at beginning of period8,22912,851
Cash and cash equivalents at end of period7,5888,22912,851
 
Supplemental disclosure of cash flow information:
Interest paid, net of amounts capitalized1,038885529
Income taxes paid3,3422,4363,137
10-K.Info (Beta Test)
Courtesy of Short Sands, LLC

GILEAD SCIENCES, INC.

Ticker: GILD   Fiscal Year: 2017

Consolidated Balance Sheets

Period Ending Dec 31, 2017 10-K (Filed: Feb 27, 2018)

(In Millions, except shares in actual)
 As ofAs of
 Dec 31, 2017Dec 31, 2016
Assets
Current assets
Cash and cash equivalents
$
7,588
8,229
Short-term marketable securities17,9223,666
Accounts receivable, net of allowances of $455 at December 31, 2017 and $763 at December 31, 20163,8514,514
Inventories8011,587
Prepaid and other current assets1,6611,592
Total current assets31,82319,588
 
Property, plant and equipment, net3,2952,865
Long-term marketable securities11,18420,485
Intangible assets, net17,1008,971
Goodwill4,1591,172
Other long-term assets2,7223,896
Total assets70,28356,977
 
Liabilities and Stockholders Equity
Current liabilities
Accounts payable8141,206
Accrued government and other rebates4,7045,021
Other accrued liabilities3,3702,991
Current portion of long-term debt and other obligations, net2,7470
Total current liabilities11,6359,218
 
Long-term debt, net30,79526,346
Long-term income taxes payable6,7941,753
Other long-term obligations558297
Commitments and contingencies (Note 12)  
Stockholders' Equity
Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding00
Common stock, par value $0.001 per share; shares authorized of 5,600 at December 31, 2017 and December 31, 2016; shares issued and outstanding of 1,308 at December 31, 2017 and 1,310 at December 31, 201611
Additional paid-in capital1,264454
Accumulated other comprehensive income165278
Retained earnings19,01218,154
Total Gilead stockholders equity20,44218,887
 
Noncontrolling interest59476
Total stockholders equity20,50119,363
 
Total liabilities and stockholders equity70,28356,977
 
External Links 
GILEAD SCIENCES, INC. (GILD) Fiscal Year 2017
Statements of 10-K in Excel https://www.sec.gov/.../Financial.xlxs
Complete 10-K in HTML https://www.sec.gov/.../10-K.html
Complete 10-K in XBRL https://www.sec.gov/.../10-K-xbrl.zip